BCAAs in Cirrhosis: Frailty Gains, Muscle Limits

Branched-chain amino acids (BCAAs) can improve frailty scores and quality of life in people with cirrhosis, but current randomized evidence does not show that they rebuild skeletal muscle. That distinction matters because sarcopenia in cirrhosis predicts worse survival and clinical outcomes; feeling and functioning better is valuable, but it is not the same outcome as reversing muscle loss.

BCAAs are leucine, isoleucine, and valine. Hepatology has used them for decades, particularly in the context of hepatic encephalopathy. The newer question is narrower: can these amino acids treat cirrhosis-related sarcopenia, and might exercise unlock a benefit that supplements alone cannot?

The best pooled evidence finds functional gains, not larger muscles

A 2026 systematic review and meta-analysis by Abuelazm et al. pooled five randomized controlled trials with 434 patients who had cirrhosis and sarcopenia. BCAA supplementation improved the Liver Frailty Index (LFI) by a mean difference of −0.14 points (95% CI, −0.28 to −0.01; P=0.03). It also improved quality of life modestly, with a standardized mean difference of 0.27 (95% CI, 0.03 to 0.52; P=0.03).

The LFI is not a throwaway wellness score. It combines grip strength, chair stands, and balance, and frailty trajectories have prognostic relevance for people awaiting liver transplantation. In a 2023 randomized trial of frail patients with compensated cirrhosis, Siramolpiwat et al. also found that BCAA supplementation improved LFI. For a patient whose daily function has narrowed, a measurable improvement in a validated frailty measure can carry real clinical weight.

But the same meta-analysis found no statistically significant improvement in the outcomes most directly tied to muscle quantity and isolated muscle performance:

• Skeletal muscle index (SMI): mean difference +0.21 cm²/m² (95% CI, −0.23 to 0.65; P=0.35).
• Handgrip strength: mean difference +0.98 kg (95% CI, −0.45 to 2.41; P=0.18).
• Gait speed: mean difference +0.10 m/s (95% CI, −0.15 to 0.34; P=0.43).
• MELD score: mean difference +0.65 (P=0.49).

That is the central result. BCAAs may help some patients function better without producing a detectable increase in CT-measured muscle mass. The trials also found a mean BMI increase of 0.99 kg/m² (95% CI, 0.16 to 1.82; P=0.02), but BMI is a poor stand-in for lean tissue in cirrhosis. Ascites and edema can raise body weight without adding muscle, and fat gain can do the same. A higher BMI with unchanged SMI should not be sold as muscle growth.

Why the muscle endpoint deserves the most attention

Sarcopenia is not cosmetic weight loss with a medical vocabulary. A 2022 meta-analysis by Tantai et al. linked sarcopenia in cirrhosis with poorer survival. In a prospective study, Luo et al. found that sarcopenia and frailty each associated with more than twice the adjusted risk of all-cause mortality; having both was associated with a hazard ratio of 4.16 (95% CI, 1.64 to 10.58; P=0.003).

Muscle and frailty do overlap, but they do not measure the same thing. Functional testing may capture balance, endurance, coordination, and the ability to use available metabolic substrate, while CT-based SMI measures muscle quantity. A 2023 study of bedside tests and CT-SMI supports the idea that functional measures and CT-based muscle assessment are related but distinct.

CT-based SMI at the third lumbar vertebra is widely treated as the reference measure for sarcopenia in cirrhosis. That rigor matters because fluid accumulation makes ordinary anthropometric estimates unreliable. Belarmino et al. specifically noted that edema and ascites limit accessible methods for estimating skeletal muscle mass. The meta-analysis's null SMI result is therefore not easily dismissed as a scale problem.

The evidence supports BCAAs as a supervised nutritional tool with functional benefits in cirrhosis. It does not support treating them as a proven muscle-building intervention.

Could exercise change the result?

The combination hypothesis is plausible. Exercise provides a mechanical signal for muscle adaptation; BCAAs provide amino-acid substrate, with leucine often viewed as an anabolic signal. Cirrhosis, however, brings hyperammonemia and sustained catabolic stress that may blunt normal anabolic responses. That explanation fits the clinical pattern, but it remains a hypothesis rather than proof from human muscle-biopsy evidence.

The most directly relevant controlled test came from Mohta et al. in 2022. This randomized, double-blind clinical trial compared BCAAs added to exercise and standard care with exercise and standard care alone in patients with cirrhosis and sarcopenia. It is the strongest available design for asking whether BCAAs add something beyond an exercise program. Yet exercise itself cannot be fully hidden from participants, so "double-blind" can only go so far in a trial whose behavioral component is visible.

A larger 2024 prospective study by Xiang et al. followed 124 participants who completed the protocol: 41 received BCAAs alone, 42 used app-guided walking alone, and 41 received both. The BCAA product supplied leucine 3,000 mg, isoleucine 750 mg, and valine 750 mg daily, as a 159-kcal late-evening snack. The combination group showed better apparent results for skeletal muscle and strength endpoints than either single-intervention group.

Those findings are interesting, not decisive. Participants entered groups according to personal preference rather than random assignment. People who choose both a supplement and a walking program may differ in motivation, baseline reserve, daily support, or willingness to adhere—variables a baseline table cannot fully capture. The study also used smartphone screenshots to monitor walking compliance rather than accelerometry or supervised observation. That leaves plenty of room for selection and reporting bias to imitate synergy.

Nutrition works in a broader context

The BCAA story should not be separated from the larger problem of nutrition in advanced liver disease. A 2023 randomized trial by Meena et al. found that home-based intensive nutrition therapy improved frailty and sarcopenia markers in patients with decompensated cirrhosis. That intervention involved broader calorie and protein support, not BCAAs alone. A wider 2026 review of oral nutritional therapy also found clinical and functional benefits with inconsistent structural muscle effects.

This context helps explain why a BCAA sachet is unlikely to be a complete answer. Cirrhosis alters appetite, nutrient use, metabolism, inflammation, activity, and fluid balance. One amino-acid formulation may improve some parts of that system without overcoming every barrier to muscle accretion.

What a definitive trial would need

The field still lacks an adequately powered trial that randomizes patients with compensated cirrhosis to BCAAs alone, exercise alone, or both; uses CT-verified SMI as its primary endpoint; follows participants for at least 24 weeks; conceals allocation; and verifies adherence objectively. It would also need consistent sarcopenia definitions. The existing randomized trials used different diagnostic thresholds and formulations, which limits direct comparison.

Until that trial arrives, BCAAs should remain a clinician-supervised part of nutritional management, not a self-prescribed sarcopenia hack. The current evidence supports a real, modest benefit for frailty and quality of life. It also sets a firm boundary: BCAA monotherapy has not shown a statistically significant increase in skeletal muscle mass, grip strength, or gait speed in the available randomized evidence.

For patients with cirrhosis, that is not a reason to ignore frailty. It is a reason to measure it alongside muscle mass, treat nutrition and physical activity as clinical issues, and avoid confusing a rise in BMI with rebuilt muscle.